The Effect of Venlafaxine and Topiramate in Reducing Migraine Headaches in Patients with Abnormal Electroencephalogram

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Neurology, Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Medicine, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

3 Epidemiologist, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Migraine disease is one of the most common human neurological diseases; although several methods have been proposed for it, but still, there is not any cure found for it. The drugs topiramate (an anticonvulsant) and venlafaxine [a serotonin-norepinephrine reuptake inhibitor (SNRI)] have been studied independently in the treatment of migraine, but their effects have not been compared. Due to the ease of access to venlafaxine and topiramate in pharmaceutical market and that the economy and side-effects of both drugs are competitive, this study aimed to compare the effects of venlafaxine and topiramate in the treatment of migraine headaches in patients with abnormal electroencephalogram (EEG).Methods: This clinical trial study was done in Noor and Imam Mousa Sadr clinic in Isfahan, Iran, during 2014. 110 patients with migraine and abnormal electroencephalogram were selected for the study after obtaining informed consent. They were distributed in two groups; group 1 received topiramate and the second group venlafaxine. After receiving 6 weeks of treatment, the duration, intensity and frequency of headache in the two groups were compared.Findings: Prior to the treatment, the intensity, frequency and duration of headache were not significantly different between the two groups (P > 0.05); but after the treatment, pain intensity was significantly lower in the group receiving venlafaxine. After the intervention, the frequency and duration of headaches were not significantly different between the two groups, too (P > 0.05).Conclusion: This study showed that the drug venlafaxine has better performance in the treatment of migraine and when there are no contraindications for its use, is recommended in patients with migraine.

Keywords

References

  1. Dash AK, Panda N, Khandelwal G, Lal V, Mann SS. Migraine and audiovestibular dysfunction: is there a correlation? Am J Otolaryngol 2008; 29(5): 295-9.
  2. Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009; 65(5): 491-8.
  3. Harno H, Hirvonen T, Kaunisto MA, Aalto H, Levo H, Isotalo E, et al. Subclinical vestibulocerebellar dysfunction in migraine with and without aura. Neurology 2003; 61(12): 1748-52.
  4. Allena M, Magis D, De Pasqua V, Schoenen J, Bisdorff AR. The vestibulo-collic reflex is abnormal in migraine. Cephalalgia 2007; 27(10): 1150-5.
  5. Mierzwinski J, Pawlak-Osinska K, Kazmierczak H, Korbal P, Muller M, Piziewicz A, et al. The vestibular system and migraine in children. Otolaryngol Pol 2000; 54(5): 537-40. [In Polish].
  6. Zhou G, Cox LC. Vestibular evoked myogenic potentials: history and overview. Am J Audiol 2004; 13(2): 135-43.
  7. Ferber-Viart C, Dubreuil C, Duclaux R. Vestibular evoked myogenic potentials in humans: a review. Acta Otolaryngol 1999; 119(1): 6-15.
  8. Hall JW. Handbook of auditory evoked responses. 2nd ed. Boston, MA: Pearson; 2007.
  9. Liao LJ, Young YH. Vestibular evoked myogenic potentials in basilar artery migraine. Laryngoscope 2004; 114(7): 1305-9.
  10. Roceanu A, Allena M, De Pasqua V, Bisdorff A, Schoenen J. Abnormalities of the vestibulo-collic reflex are similar in migraineurs with and without vertigo. Cephalalgia 2008; 28(9): 988-90.
  11. Ghali AA, Kolkaila EA. Migrainous vertigo: clinical and vestibular evoked myogenic potential (VEMP) findings. Egypt J Neurol Psychiat Neurosurg 2005; 42(2): 341-50.
  12. Wu ZM, Zhang SZ, Zhou N, Liu XJ, Ji F, Chen AT, et al. Neurootological manifestation of migrainous vertigo. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2006; 41(10): 726-30. [In Chinese].
  13. Baier B, Stieber N, Dieterich M. Vestibular-evoked myogenic potentials in vestibular migraine. J Neurol 2009; 256(9): 1447-54.
  14. International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988; 8(Suppl 7): 1-96.
  15. Vanspauwen R, Wuyts FL, Van De Heyning PH. Validity of a new feedback method for the VEMP test. Acta Otolaryngol 2006; 126(8): 796-800.
  16. Vanspauwen R, Wuyts FL, Van De Heyning PH. Improving vestibular evoked myogenic potential reliability by using a blood pressure manometer. Laryngoscope 2006; 116(1): 131-5.
  17. Sandhu JS, Bell SL. Effects of eye position on the vestibular evoked myogenic potential. Acta Otolaryngol 2009; 129(2): 175-8.
  18. Zapala D. The VEMP: ready for the clinic. Hear J 2007; 60(3): 10,14,16-8,20.
  19. Parker W. Migraine and the vestibular system in adults. Am J Otol 1991; 12(1): 25-34.
  20. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007; 27(11): 1293-300.
  21. Cass SP, Furman JM, Ankerstjerne K, Balaban C, Yetiser S, Aydogan B. Migraine-related vestibulopathy. Ann Otol Rhinol Laryngol 1997; 106(3): 182-9.
  22. Murofushi T, Ozeki H, Inoue A, Sakata A. Does migraine-associated vertigo share a common pathophysiology with Meniere's disease? Study with vestibular-evoked myogenic potential. Cephalalgia 2009; 29(12): 1259-66.
  23. Murofushi T, Shimizu K, Takegoshi H, Cheng PW. Diagnostic value of prolonged latencies in the vestibular evoked myogenic potential. Arch Otolaryngol Head Neck Surg 2001; 127(9): 1069-72.
  24. Welgampola MS, Colebatch JG. Characteristics and clinical applications of vestibular-evoked myogenic potentials. Neurology 2005; 64(10): 1682-8.
  25. Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RS, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 2005; 128(Pt 4): 932-9.
  26. Brunton L, Chabner B, Knollman B. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. New New York, NY: McGraw-Hill; 2011.
Journal of Isfahan Medical School
Volume 33, Issue 326 - Serial Number 326
January and February 2015
Pages 287-293

Files

History

  • Receive Date: 22 September 2014
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics